Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Dosing regimen  





2 See also  





3 References  














BEACOPP






العربية
Deutsch
Nederlands
Русский
Suomi
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group[1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors.[2] Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21.[3] There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD. In some countries BEACOPP still is experimental, in others (e.g. Germany and Austria) it is a standard therapy. In the United States, ABVD (orStanford V) is generally given instead, because BEACOPP is perceived by practicing oncologists to have the potential to induce more secondary neoplasias (such as leukemias). However, the final results from the GHSG HD14 trial indicate that『there were no overall differences in treatment-related mortality or secondary malignancies』of BEACOPP relative to ABVD.[2]

Oncologists in the US have also used the BEACOPP regimen relatively less for cost reasons:

However, BEACOPP delivers approximately 7% points success relative to ABVD for early unfavorable Hodgkin's disease (as measured five-year freedom from treatment failure)[2] and 12% points greater success relative to ABVD for advanced Hodgkin's disease (Stage IIB with risk factors or stages III and IV) as measured by seven-year freedom from treatment failure.[6]

Predecessors of BEACOPP were COPP and (the earliest) MOPP.

Dosing regimen

[edit]
Drug Base BEACOPP Dose-Escalated BEACOPP Method Cycle Day
(B)leomycin 10 mg/m2 10 mg/m2 i.v. push day 8
(E)toposide 100 mg/m2 200 mg/m2 i.v. infusion day 1–3
(A)driamycin (doxorubicin) 25 mg/m2 35 mg/m2 i.v. push day 1
(C)yclophosphamide 650 mg/m2 1250 mg/m2 i.v. infusion day 1
(O)ncovin=Vincristine 1.4 mg/m2 (max 2 mg) 1.4 mg/m2 (max 2 mg) i.v. infusion day 8
(P)rocarbazine 100 mg/m2 100 mg/m2 orally day 1–7
(P)rednisone 40 mg/m2 40 mg/m2 orally day 1–14

See also

[edit]

References

[edit]
  • ^ a b c von Tresckow, Bastian; et al. (March 20, 2012). "Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial". Journal of Clinical Oncology. 30 (9): 907–913. doi:10.1200/JCO.2011.38.5807. PMID 22271480. Retrieved 2013-01-24.
  • ^ See HD14 Redacted Trial Protocol, available at
  • ^ "Neupogen". Fierce Pharma. Retrieved 2013-01-24.
  • ^ "Amgen And Its Biosimilar Competitors". SeekingAlpha. Retrieved 2013-01-24.
  • ^ Viviani, Simonetta; et al. (July 21, 2011). "ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned". New England Journal of Medicine. 365 (3): 203–212. doi:10.1056/nejmoa1100340. PMID 21774708.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=BEACOPP&oldid=1170167605"

    Categories: 
    Chemotherapy regimens used in lymphoma
    Hodgkin lymphoma
     



    This page was last edited on 13 August 2023, at 14:01 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki